UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025
UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.
UBC Announces Partnership with Osmind to Advance the Future of Mental Health Treatment and Research within REMS
First-of-its-kind partnership in mental health care reduces REMS implementation burden, improves the quality of REMS data, and optimizes safe medication use and health outcomes
